Amphotericin B is complexed with deoxycholate (C-AMB) and marketed as a lyophilized powder (fungizone) containing 50 mg of amphotericin B that forms a colloid in water. Three lipid formulations of amphotericin B are marketed in the U.S. Amphotericin B colloidal dispersion (ABCD, amphotec, amphocil) contains equimolar amounts of amphotericin B and cholesteryl sulfate. ambisome is a small, unilamellar vesicle formulation that combines amphotericin B (50 mg) with 350 mg of lipid (phosphatidylcholine, cholesterol, and distearoylphosphatidylglycerol, in molar ratio of 10:5:4) in an ~10% molar ratio. Amphotericin B lipid complex (ABLC, abelcet) contains dimyristoylphosphatidylcholine and dimyristoylphosphatidylglycerol in a 7:3 mixture with ~35 mol% of amphotericin B.
The role of lipid formulations of amphotericin B in fungal infections remains to be determined. The risk of adverse effects such as nephrotoxicity is decreased by ~50% with lipid formulations, but they cost 20—50 times more and may be associated with a greater risk of febrile infusion reactions.
Was this article helpful?
Your heart pumps blood throughout your body using a network of tubing called arteries and capillaries which return the blood back to your heart via your veins. Blood pressure is the force of the blood pushing against the walls of your arteries as your heart beats.Learn more...